Skip to content

Study · Measured the body's own peptide · 1992

4 results

Plasma levels of DSIP in infants in the first year of life and SIDS risk.

Scholle S, Zwacka G, Ekman R, Glaser S

Regulatory peptides1 Apr 1992Cited by 1 (Europe PMC)

PMID1579657 (opens in a new tab)DOI10.1016/0167-0115(92)90005-f (opens in a new tab)PepBankPUB-01579657
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In infants in the first year of life, the plasma level of the body's own DSIP did not depend on age.

    In plain wordsIn infants, natural DSIP levels in blood did not change with age during the first year.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changePlasma DSIP and age in the first year of life
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep

    Source sentences

    Summary
    There was no age dependence of the plasma level of DSIP in the first year of life
    1 context sentence
    Summary · context
    was investigated in the first year of life in four groups of children: (1) preterm infants (n = 28), (2) infants with a high mean apnea duration evaluated polysomnographically (n = 26), (3) healthy full-term infants (n = 37) and (4) siblings of SIDS-victims (n = 26).

    This result measures the body's own Delta sleep-inducing peptide (DSIP). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    Plasma DSIP, the body's own peptide, was significantly higher in healthy full-term infants than in preterm infants.

    In plain wordsHealthy full-term infants had higher natural DSIP levels in blood than preterm infants.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    IncreasePlasma DSIP in healthy full-term infants versus preterm infants
    Study

    n: not reported in source

    Comparator
    Preterm infants
    Outcome group
    Sleep · Sleep

    Measurements

    Plasma DSIP median
    1885 pmol/l
    healthy full-term infants
    Plasma DSIP median
    1595 pmol/l
    preterm infants

    Source sentences

    Summary
    The level of DSIP in healthy full-term infants was significantly higher (P less than 0.05) (median: 1885 pmol/l, interquartile range: 757 pmol/l) than in preterms (1595; 385) and in infants with a high mean apnea duration (1542; 373).
    1 context sentence
    Summary · context
    was investigated in the first year of life in four groups of children: (1) preterm infants (n = 28), (2) infants with a high mean apnea duration evaluated polysomnographically (n = 26), (3) healthy full-term infants (n = 37) and (4) siblings of SIDS-victims (n = 26).

    This result measures the body's own Delta sleep-inducing peptide (DSIP). Nobody was given the peptide. It is not evidence about taking it.

  3. 03HumanEndogenous levelObservational studyOther

    Plasma DSIP, the body's own peptide, was significantly higher in healthy full-term infants than in infants with a high mean apnea duration.

    In plain wordsHealthy full-term infants had higher natural DSIP levels in blood than infants with long breathing pauses.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    IncreasePlasma DSIP in healthy full-term infants versus infants with high mean apnea duration
    Study

    n: not reported in source

    Comparator
    Infants with a high mean apnea duration
    Outcome group
    Sleep · Sleep

    Measurements

    Plasma DSIP median
    1885 pmol/l
    healthy full-term infants
    Plasma DSIP median
    1542 pmol/l
    infants with a high mean apnea duration

    Source sentences

    Summary
    The level of DSIP in healthy full-term infants was significantly higher (P less than 0.05) (median: 1885 pmol/l, interquartile range: 757 pmol/l) than in preterms (1595; 385) and in infants with a high mean apnea duration (1542; 373).
    1 context sentence
    Summary · context
    was investigated in the first year of life in four groups of children: (1) preterm infants (n = 28), (2) infants with a high mean apnea duration evaluated polysomnographically (n = 26), (3) healthy full-term infants (n = 37) and (4) siblings of SIDS-victims (n = 26).

    This result measures the body's own Delta sleep-inducing peptide (DSIP). Nobody was given the peptide. It is not evidence about taking it.

  4. 04HumanEndogenous levelObservational studyOther

    Plasma DSIP, the body's own peptide, did not differ significantly between healthy full-term infants and siblings of SIDS victims.

    In plain wordsNatural DSIP levels in blood were similar in healthy full-term infants and siblings of SIDS victims.

    Peptide
    Delta sleep-inducing peptide (DSIP)
    Outcome
    No significant changePlasma DSIP in healthy full-term infants versus SIDS siblings
    Study

    n: not reported in source

    Comparator
    Siblings of SIDS victims
    Outcome group
    Sleep · Sleep

    Measurements

    Plasma DSIP median
    1605 pmol/l
    siblings of SIDS victims

    Source sentences

    Summary
    There was no significant difference in DSIP concentrations between healthy full-term infants and SIDS-siblings (1605; 271).
    1 context sentence
    Summary · context
    was investigated in the first year of life in four groups of children: (1) preterm infants (n = 28), (2) infants with a high mean apnea duration evaluated polysomnographically (n = 26), (3) healthy full-term infants (n = 37) and (4) siblings of SIDS-victims (n = 26).

    This result measures the body's own Delta sleep-inducing peptide (DSIP). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.